SCR-LIP-000357 · Claim · machine-readable JSON →
In a Swiss cohort of 239 lipedema patients assessed with validated questionnaires, 64.4% had anxiety (HADS≥8), 23.4% had depression (HADS≥8), and low quality of life was found in 71.5% (PCS-SF36) and 67.4% (MCS-SF36), with none of these psychosocial parameters differing significantly across disease stages (p>0.5).
Claim at a glance
- Type
- clinical association
- Knowledge state
- Emerging
- Evidence certainty
- moderate (GRADE)
- Evidence
- 1 source(s)
- Answers
- 3 question(s)
- Dates
- 2026-05-31 → 2026-05-31
Structured evidence, machine-compiled — not a verdict.
Auto-compiled by the Layer 1 surveillance loop; not yet human-reviewed. anthropic/claude-opus-4.8 · 2026-05-31
Evidence over time
Evidence (1)
- Clinical characteristics, comorbidities, and correlation with advanced lipedema stages: A retrospective study from a Swiss referral centre — Luta et al. (2025) ✓ verified — consistent · cross sectional · 2025 · reading confidence: high
Retrospective referral-centre study with validated instruments (SF-36, HADS, BPI, FSS) directly quantifying quality of life, depression, and anxiety in lipedema patients, showing high psychosocial burden dissociated from disease stage.
Context (PECO)
Answers these questions
- How does lipedema affect quality of life, depression, and anxiety in affected patients? consistent
- How does lipedema affect health-related quality of life? consistent
- How does lipedema affect mental health (depression and anxiety)? consistent
Gaps & caveats
Auto-ingested single source; not yet human-reviewed.
Change log
- 2026-05-31 — created · auto-ingested for SQ-LIP-000020